I decided to buy Decode Genetics DCGN nasdaq because I thought the company had taken some recent hits that might pass over. I still think I am right. I think DeCode with the launch of their new products and research will someday soon return to levels of over $5 a share. If you are looking for a good long term buy I think it is worth while. I will probably buy more next week. It is not a stock to pick up for a quick buck. However, it is value priced right now and I think they might be sitting on a big break. Again, a roll of the dice but I think these dice are loaded.

Here’s a brief bit of intro from their new breast cancer test.

REYKJAVIK, Iceland, Oct. 8 /PRNewswire-FirstCall/ — deCODE genetics (Nasdaq: DCGN – News) today announced the launch of deCODE BreastCancer(TM), a new tool for assessing risk of the common forms of breast cancer. For the first time, a woman concerned about breast cancer can speak with her physician about a genetic test to better understand her lifetime risk of developing the common forms of the disease.

“This test is simple and compelling because it provides a woman and her doctor a means of understanding her personal risk of developing the common forms of breast cancer. This information is well-validated, relevant to the vast majority of women, and independent of family history and other known risk factors. Combined with the high public awareness of the importance of screening, advances in magnetic resonance imaging (MRI) technology and the availability of preventive drugs targeting estrogen receptors, I believe this test will help to save lives,” said Dr. Kari Stefansson, M.D., Dr. Med., CEO of deCODE.

View admin's Profile      Subscribe via RSS